Meningitis: What It Is and How to Avoid It Watch Video

Colistimethate Sodium

Class: Polymyxins
VA Class: AM900
CAS Number: 8068-28-8
Brands: Coly-Mycin M

Warning(s)

Special Alerts:

[Posted 06/30/2011] A National Alert for Serious Medication Errors has been issued by the American Society of Health-System Pharmacists (ASHP) and the Institute for Safe Medication Practices (ISMP), warning that potentially fatal errors may occur with dosing for the antibiotic colistimethate for injection. The use of this drug has been increasing due to its value as a last resort treatment for multi-drug resistant organisms.

Colistimethate is a prodrug, a pre-cursor of a drug that converts to an active drug in the human body as it is metabolized. However, in the U.S., the strength of all FDA-approved colistimethate for injection products is labeled in terms of the base drug, colistin, not the prodrug. The label expresses the strength as 150 mg of colistin base per vial.

Dosing information also is expressed in terms of the colistin base. However, on the Internet and in some journal references, dosing information is based on the prodrug, colistimethate. This has resulted in situations where the prodrug dose is ordered but confused as a colistin dose, which results in doses approximately 2.5 times higher than intended.

In a recent case, a physician mistakenly ordered a dose of colistimethate as the prodrug, but the amount was dispensed as the colistin base. The patient developed complications including acute renal failure and later died.

The alert provides recommendations to prevent misdosing of colistimethate, which include developing dose limits, restricting prescribing to infectious disease specialists, and monitoring the patients’ renal function. Physicians, pharmacists, and nurses are expected to use these recommendations to take immediate action to prevent serious medication errors at their facility.

Alerts are issued by ASHP and ISMP when a significant risk for serious or fatal errors is detected through ISMP’s National Medication Error Reporting Program (MERP). Alerts are distributed to healthcare practitioners and organizations through ISMP, ASHP, and the National Council on Medication Error Reporting and Prevention.

Introduction

Antibacterial; sulfamethyl derivative (methane sulfonate) of colistin that is hydrolyzed to colistin in vitro (in aqueous solutions) and in vivo.134 Colistin (polymyxin E) is a polymyxin antibiotic structurally and pharmacologically related to polymyxin B.134

Uses for Colistimethate Sodium

Gram-negative Aerobic Bacterial Infections

Treatment of acute or chronic infections caused by certain susceptible gram-negative bacteria (e.g., Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa).100

Used only when the causative agent is susceptible and other more effective and less toxic anti-infectives are contraindicated or ineffective.a

May be useful alone or in conjunction with other anti-infectives for treatment of infections caused by multiple-drug resistant gram-negative bacteria, such as respiratory tract infections in cystic fibrosis patients caused by multiple-drug resistant Ps. aeruginosa.106 119 121 122 135

Slideshow: Worried About Ebola? You’re More Likely to Get These 10 Serious Infections

Not indicated for infections caused by Proteus or Neisseria.100

Respiratory Tract Infections

Administered by oral inhalation via nebulization in adult and pediatric cystic fibrosis patients for early treatment of Ps. aeruginosa respiratory tract infections and for suppressive therapy in those colonized with Ps. aeruginosa.109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126

Safety and efficacy not established and the drug is not labeled by FDA for administration via nebulization.109 110 Adverse respiratory effects (e.g., bronchoconstriction) have occurred with this route119 130 131 and there has been at least one fatality in a patient who self-administered a nebulizer treatment using a premixed solution of the drug.109 110 (See Respiratory Effects under Cautions.)

Colistimethate Sodium Dosage and Administration

Administration

Administer by IM injection, IV injection, or continuous IV infusion.100 Also has been administered by oral inhalation via nebulization.109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126

Solutions for IM injection, IV injection, or continuous IV infusion should be freshly prepared and used within 24 hours.100

Extemporaneously prepared solutions for nebulization should be used promptly after being prepared.109 A fatality has been reported in a cystic fibrosis patient who self-administered a nebulizer treatment using a premixed solution of the drug.109 110 (See Respiratory Effects under Cautions.)

IM Administration

Reconstitution

Reconstitute colistimethate sterile powder by adding 2 mL of sterile water for injection to a vial labeled as containing 150 mg of colistin; swirl gently to avoid frothing.100 The resultant solution contains 75 mg of colistin per mL.100

Inject the appropriate dose of reconstituted solution IM.100

IV Injection

Reconstitution

Reconstitute colistimethate sterile powder by adding 2 mL of sterile water for injection to a vial labeled as containing 150 mg of colistin; swirl gently to avoid frothing.100 Resultant solution contains 75 mg of colistin per mL.100

Rate of Administration

Inject the appropriate dose of reconstituted solution directly into a vein over 3–5 minutes.100

IV Infusion

For solution and drug compatibility information, see Compatibility under Stability.

Reconstitution and Dilution

Reconstitute colistimethate sterile powder by adding 2 mL of sterile water for injection to a vial labeled as containing 150 mg of colistin; swirl gently to avoid frothing.100 Resultant solution contains 75 mg of colistin per mL.100

Add one-half of the total daily dose to a compatible IV solution.100 (See Compatibility under Stability.)

Rate of Administration

Inject one-half of the total daily dose directly into a vein over 3–5 minutes (as reconstituted solution), then administer the dilution containing the remaining one-half of the total daily dose by slow IV infusion over 22–23 hours beginning 1–2 hours after the injection.100

The infusion rate should be 5–6 mg/hour in patients with normal renal function.a Reduce rate depending on the degree of renal impairment.100

Oral Inhalation

For oral inhalation via nebulization, an isotonic solution has been prepared by diluting the appropriate dose in 2–4 mL of preservative-free 0.9% sodium chloride injection, sterile water, or a mixture of 0.9% sodium chloride injection and sterile water.110 111 112 114 115 121 126 131

Extemporaneously prepared solutions for nebulization should be used promptly after being prepared.109 A fatality has been reported in a cystic fibrosis patient who self-administered a nebulizer treatment using a premixed solution of the drug.109 110 (See Respiratory Effects under Cautions.)

Bronchoconstriction has occurred almost immediately after initiation of nebulization;119 premedication with bronchodilators can be used to reduce the potential for bronchoconstriction.119 120 122 130 131 (See Respiratory Effects under Cautions.)

Dosage

Available as colistimethate sodium.100

Dosage of colistimethate sodium commercially available in the US is expressed in terms of colistin base.100

Dosage of colistimethate sodium preparations commercially available in some other countries (e.g., United Kingdom, Greece) is expressed in terms of colistimethate sodium or in terms of international units.111 112 113 114 115 116 117 118 121 129 The fact that dosages reported in published clinical studies or case reports may vary depending on the preparation used should be considered.120 129

To avoid confusion, it has been suggested that dosage of colistimethate should preferably be expressed in terms of international units.129 135 When expressed in terms of international units, each mg of colistin base has a potency of 30,000 international units129 134 and each mg of colistimethate sodium has a potency of 12,500 international units.129

Dosage is identical for either IV or IM administration.100

Pediatric Patients

General Dosage for Infants and Children
IM or IV Injection

2.5–5 mg/kg of colistin daily given in 2–4 divided doses, depending on the severity of the infection.100

Continuous IV Infusion

2.5–5 mg/kg of colistin daily, depending on the severity of the infection.100 Give the first half of the dose by direct IV injection and the second half of the dose by slow IV infusion over 22–23 hours beginning 1–2 hours after the injection.100

Pseudomonas aeruginosa Infections in Cystic Fibrosis Patients
Oral Inhalation

33.33–66.66 mg of colistin 2 or 3 times daily.111 112 113 114 115 117 128 This corresponds to 1–2 million international units 2 or 3 times daily.111 112 113 114 115 116 117 121 128

Adults

General Adult Dosage
IM or IV Injection

2.5–5 mg/kg of colistin daily given in 2–4 divided doses, depending on the severity of the infection.100

Continuous IV Infusion

2.5–5 mg/kg of colistin daily, depending on the severity of the infection.100 Give the first half of the dose by direct IV injection and the second half of the dose by slow IV infusion over 22–23 hours beginning 1–2 hours after the injection.100

Pseudomonas aeruginosa Infections in Cystic Fibrosis Patients
Oral Inhalation

33.33–66.66 mg of colistin 2 or 3 times daily.111 112 113 114 115 117 128 This corresponds to 1–2 million international units 2 or 3 times daily.111 112 113 114 115 116 117 121 128

Prescribing Limits

Pediatric Patients

IM or IV

Maximum of 5 mg/kg of colistin daily in those with normal renal function.100

Adults

IM or IV

Maximum of 5 mg/kg of colistin daily in those with normal renal function.100

Special Populations

Hepatic Impairment

No specific dosage recommendations at this time.100

Renal Impairment

Adjust IM or IV dosage in patients with renal impairment.100 Decrease IM or IV dose and frequency in proportion to the degree of renal impairment.100 (See Table.)

Dosage for Adults with Renal Impairment100

Scr (mg/100mL)

IM or IV Dose (mg)

Frequency (times/day)

Total daily dose (mg)

Approximate daily dose (mg/kg/day)

0.7–1.2

100–150

2–4

300

5

1.3–1.5

75–115

2

150–230

2.5–3.8

1.6–2.5

66–150

1–2

133–150

2.5

2.6–4

100–150

every 36 hours

100

1.5

Geriatric Patients

Select IM or IV dosage with caution, usually initiating therapy at the low end of the dosage range.100 Consider the greater frequency of decreased hepatic, renal, and/or cardiac function and of concomitant disease and drug therapy observed in the elderly.100

Obese Patients

Base dosage on ideal body weight.100

Cautions for Colistimethate Sodium

Contraindications

  • Hypersensitivity to colistimethate or any ingredient in the formulation.100

Warnings/Precautions

Warnings

Nephrotoxicity

Nephrotoxicity (decreased urine output, increased BUN and Scr, proteinuria, hematuria, casts in the urine) reported with usual dosage.a Acute tubular necrosis has been reported and was not necessarily preceded by progressive renal impairment.a

Nephrotoxicity generally reversible when the drug is discontinued.a Additional increases in Scr frequently occur for 1–2 weeks following discontinuance of the drug.a

Monitor renal function.a Nephrotoxicity probably is dose-dependent,100 but adverse renal effects may occur regardless of dosage.a

Use with caution in patients in whom the possibility of renal impairment exists (e.g., geriatric patients).100

Discontinue drug immediately if diminishing urine output, increasing BUN or Scr, or decreased Clcr occur.100 If colistimethate must be reinstated, dosage should be adjusted after plasma concentrations of the drug have declined.100 (See Renal Impairment under Dosage and Administration.)

Neurotoxicity

Transient neurologic effects reported, including circumoral or peripheral paresthesia or numbness, tingling, or formication of the extremities or tongue, generalized pruritus, dizziness, vertigo, giddiness, ataxia, blurred vision, and slurred speech.100 a

If neurologic effects occur, they generally appear within the first 4 days of therapy and disappear upon discontinuing the drug.a

More severe neurotoxic effects (e.g., mental confusion, coma, psychosis, seizures) also reported, especially when high dosage was used or renal function was impaired.a

The drug does not necessarily have to be discontinued if neurologic effects occur, but monitor patient closely; some of these effects may be alleviated by reducing dosage.100 a

Patients should not drive vehicles or use hazardous machinery while receiving colistimethate.100

Neuromuscular Blockade

Neuromuscular blockade (which may result in respiratory arrest) can occur, especially when used in patients who have neuromuscular disease such as myasthenia gravis or are receiving neuromuscular blocking agents, general anesthetics, or other drugs with neuromuscular blocking potential.a (See Specific Drugs under Interactions.)

Apnea and neuromuscular blockade reported most frequently when dosage was not reduced in proportion to the degree of renal impairment.a

If apnea occurs, respiration should be assisted, and calcium chloride injections and oxygen administered if appropriate.a

Neuromuscular blockade induced by colistimethate is noncompetitive and is not reversed by neostigmine.a

Respiratory Effects

Administration by oral inhalation via nebulization has caused bronchoconstriction in adult and pediatric cystic fibrosis patients.119 130 131 Bronchoconstriction has occurred almost immediately after initiation of nebulization and can last for >30 minutes.119

Premedication with bronchodilators may reduce the potential for bronchoconstriction.119 120 122 130 131

Pre- and posttreatment pulmonary function tests recommended to identify patients who may be predisposed to bronchoconstriction.119 Bronchodilator premedication recommended in young children who are unable to perform pulmonary function tests.131

Respiratory distress progressing over several days to acute respiratory failure, multi-organ system failure, and death was reported in a patient who received colistimethate by oral inhalation via nebulization.109 110 This patient self-administered the nebulizer treatment using a colistimethate solution prepared by a pharmacy and dispensed in premixed unit dose ready-to-use vials.109 110 This fatality may have been related to the fact that a premixed solution of colistimethate was used in the nebulizer.109 110

Extemporaneously prepared solutions of colistimethate should be used promptly.109 After colistimethate is mixed with water and buffer, it undergoes spontaneous hydrolysis to colistin.110 A component of colistin (polymyxin E1) has been shown to cause pulmonary inflammatory reactions in animals and may contribute to such local toxicity in humans.109 110 119

Respiratory arrest reported following IM administration.100

Clostridium difficile-associated Diarrhea and Colitis

Treatment with anti-infectives may permit overgrowth of Clostridium difficile.100 101 102 103 104 105 C. difficile-associated diarrhea and colitis (CDAD; also known as antibiotic-associated diarrhea and colitis or pseudomembranous colitis) has been reported with nearly all anti-infectives, including colistimethate, and may range in severity from mild diarrhea to fatal colitis.100 101 102 103 104 105

Consider CDAD if diarrhea develops during or after therapy and manage accordingly.100 101 102 103 104 105 Careful medical history is necessary since CDAD has been reported to occur as late as 2 months or longer after anti-infective therapy is discontinued.100

If CDAD is suspected or confirmed, discontinuance of the anti-infective may be necessary.100 101 102 103 104 105 Some mild cases may respond to discontinuance alone.100 101 102 103 104 105 Manage moderate to severe cases with fluid, electrolyte, and protein supplementation, anti-infective therapy active against C. difficile (e.g., oral metronidazole or vancomycin), and surgical evaluation when clinically indicated.100 101 102 103 104 105

General Precautions

Superinfection

Prolonged use may result in overgrowth of nonsusceptible organisms (e.g., Proteus).a If suprainfection or superinfection occurs during therapy, appropriate anti-infective therapy should be instituted.a

Selection and Use of Anti-Infectives

To reduce development of drug-resistant bacteria and maintain effectiveness of colistimethate and other antibacterials, use only for treatment or prevention of infections proven or strongly suspected to be caused by susceptible bacteria.100

When selecting or modifying anti-infective therapy, use results of culture and in vitro susceptibility testing.100 In the absence of such data, consider local epidemiology and susceptibility patterns when selecting anti-infectives for empiric therapy.100

Specific Populations

Pregnancy

Category C.100

Lactation

Not known whether colistimethate is distributed into milk;100 colistin is distributed into milk.100 Use with caution.100

Pediatric Use

Used in neonates, infants, children, and adolescents.100 Adverse effect profile in pediatric patients appears to be similar to that in adults; however, monitor closely since subjective symptoms of toxicity may not be reported by pediatric patients.100

Geriatric Use

Insufficient experience in patients ≥65 years of age to determine whether geriatric patients respond differently than younger adults.100 Other clinical experience has not revealed age-related differences in response.100

Select dosage with caution, usually starting at the low end of the dosage range, because of age-related decreases in hepatic, renal, and/or cardiac function and concomitant disease and drug therapy.100

Substantially eliminated by kidneys; risk of toxicity may be greater in those with impaired renal function.100 Consider monitoring renal function because of age-related decreases in renal function.100 (See Renal Impairment under Dosage and Administration.)

Renal Impairment

Use with caution in patients in whom the possibility of renal impairment exists (e.g., geriatric patients).100

If used in patients with renal impairment, reduce dosage and frequency of administration in proportion to the degree of impairment.100 (See Renal Impairment under Dosage and Administration.)

Dosage that exceeds renal excretory capacity will lead to high serum concentrations of the drug, which can result in further impairment of renal function and possibly acute renal insufficiency, renal shutdown, and neuromuscular blockade.100

Discontinue drug immediately if diminishing urine output, increasing concentrations of BUN or Scr, or decreased Clcr occur.100

Common Adverse Effects

Renal effects, nervous system effects.100

Interactions for Colistimethate Sodium

Neurotoxic or Nephrotoxic Drugs

Concomitant or sequential use with other drugs that have neurotoxic and/or nephrotoxic effects may result in additive toxicity and should be avoided, if possible.100 a

Specific Drugs

Drug

Interaction

Comments

Aminoglycosides

Possible increased risk of nephrotoxic and/or neurotoxic effects;100 a possible potentiation of neuromuscular blockade100

Use caution;100 avoid concurrent or sequential use, if possiblea

Amphotericin B

Possible increased risk of nephrotoxic and/or neurotoxic effectsa

Avoid concurrent or sequential use, if possiblea

Capreomycin

Possible increased risk of nephrotoxic and/or neurotoxic effectsa

Avoid concurrent or sequential use, if possiblea

Neuromuscular blocking agents and general anesthetics (succinylcholine, tubocurarine, ether, decamethonium)

Possible potentiation of neuromuscular blockade100 a

Use extreme caution100

Polymyxin B sulfate

Possible increased risk of nephrotoxic and/or neurotoxic effects;100 a possible potentiation of neuromuscular blockade100

Use caution;100 avoid concurrent or sequential use, if possible100 a

Vancomycin

Possible increased risk of nephrotoxic and/or neurotoxic effectsa

Avoid concurrent or sequential use, if possiblea

Colistimethate Sodium Pharmacokinetics

Absorption

Bioavailability

Not absorbed orally;a must be given parenterally.a

Following IM administration, peak serum concentrations attained within 2 hours.a

Special Populations

Following IV administration of colistimethate sodium in a dosage of 5–7 mg/kg of colistin daily given in 3 equally divided doses (maximum 70–100 mg every 8 hours) in cystic fibrosis patients 14–53 years of age, mean peak serum concentrations after first dose and at steady state are 21.4 mcg/mL and 23 mcg/mL, respectively;133 mean 8-hour trough concentrations after first dose and at steady state are 2.8 mcg/mL and 4.5 mcg/mL, respectively.133

Following oral inhalation via nebulization of colistimethate sodium in a dosage of 66.66 mg of colistin (2 million international units) in cystic fibrosis patients 12–48 years of age, peak serum concentrations of 0.17 mcg/mL are attained in 1.5 hours.132

Distribution

Extent

Widely distributed into body tissues following IV or IM administration.a Negligible concentrations attained in synovial, pleural, or pericardial fluids.a

Minimal concentrations attained in CSF following IV or IM administration in patients with normal or inflamed meninges.a

Crosses placenta.100

Not known whether colistimethate is distributed into milk; colistin is distributed into milk.100

Plasma Protein Binding

>50% bound.a

Special Populations

Following IV administration in cystic fibrosis patients 14–53 years of age, steady state volume of distribution is 0.09 L/kg.133

Following oral inhalation via nebulization in cystic fibrosis patients 12–48 years of age, sputum concentrations peaked in 1 hour and remained >4 mcg/mL for up to 12 hours in most patients.132

Elimination

Metabolism

Hydrolyzed in vivo to colistin and possibly other metabolites with fewer substituted amino groups.a Rate and extent of hydrolysis as well as the specific metabolites and their antibacterial activities have not been determined to date.a

Elimination Route

Excreted mainly by the kidneys via glomerular filtration.a Antimicrobial activity in urine generally higher than in serum.a

May be removed by hemodialysis and, to a lesser extent, by peritoneal dialysis.134

Half-life

1.5–8 hours in adults with normal renal function.a

Special Populations

Children: Serum concentrations decline more rapidly than in adults.a

Impaired renal function: Serum concentrations are higher and the half-life prolonged.a Half-life ranges from 10–20 hours in patients with Clcr <20 mL/minute.a In a few anuric patients, half-life of antimicrobial activity ranged from 2–3 days.a

Cystic fibrosis patients 14–53 years of age receiving IV colistimethate: Half-life is 3.4 hours after the first dose and 3.5 hours at steady state.133

Cystic fibrosis patients 12–48 years of age receiving colistimethate by oral inhalation via nebulization: Half-life is 4.1–4.5 hours.132

Stability

Storage

Parenteral

Powder for Injection

20–25°C.100

Following reconstitution, store at 2–8°C or 20–25°C and use within 7 days.100

Reconstituted solutions further diluted with a compatible IV solution should be used within 24 hours.100

Extemporaneously prepared solutions for oral inhalation via nebulization should be used promptly after being mixed.109 (See Respiratory Effects under Cautions.)

Compatibility

For information on systemic interactions resulting from concomitant use, see Interactions.

Parenteral

Solution Compatibility

Compatible100

Dextrose 5% in 0.225%, 0.45%, or 0.9% sodium chloride

Dextrose 5% in water

Invert sugar 10%

Ringer’s injection, lactated

Sodium chloride 0.9%

Drug Compatibility
Admixture CompatibilityHID

Compatible

Amikacin sulfate

Ascorbic acid injection

Chloramphenicol sodium succinate

Diphenhydramine HCl

Heparin sodium

Penicillin G potassium

Penicillin G sodium

Phenobarbital sodium

Polymyxin B sulfate

Ranitidine HCl

Incompatible

Erythromycin lactobionate

Hydrocortisone sodium succinate

Y-Site CompatibilityHID

Variable

Telavancin HCl

Actions and Spectrum

  • Inactive until hydrolyzed to colistin;a hydrolysis occurs in vitro in aqueous solutions and in vivo.a

  • Usually bactericidal.a

  • Acts like a cationic detergent and binds to and damages bacterial cytoplasmic membrane of susceptible bacteria causing alteration of the osmotic barrier and leakage of essential intracellular metabolites and nucleosides.a

  • In vitro spectrum of activity includes certain gram-negative bacteria.100 a Inactive against gram-positive bacteria, fungi, and viruses.a

  • Gram-negative bacteria: Active in vitro against Acinetobacter, Citrobacter, Escherichia coli, Enterobacter, Haemophilus influenzae, Klebsiella pneumoniae, Pseudomonas aeruginosa, Salmonella, Shigella, and some strains of Bordetella and Vibrio.100 a Most strains of Proteus, Providencia, Serratia, Neisseria gonorrhoeae, N. meningitidis, and Bacteroides fragilis are resistant to colistin.100 a

  • Resistance has been induced in vitro in strains originally susceptible.a Resistance may be reversible when drug is withdrawn.a Resistance developed rarely during therapy.a

  • Resistant Ps. aeruginosa reported rarely, including in some patients receiving long-term treatment with colistimethate administered by oral inhalation via nebulization.122 134

  • Resistant Acinetobacter baumannii,136 Enterobacter cloacae,138 and Klebsiella pneumoniae reported rarely.137 138

  • Complete cross-resistance occurs between colistin and polymyxin B;134 cross-resistance with other anti-infectives has not been reported to date.a

Advice to Patients

  • Advise patients that antibacterials (including colistimethate) should only be used to treat bacterial infections and not used to treat viral infections (e.g., the common cold).100

  • Importance of completing full course of therapy, even if feeling better after a few days.100

  • Advise patients that skipping doses or not completing the full course of therapy may decrease effectiveness and increase the likelihood that bacteria will develop resistance and will not be treatable with colistimethate or other antibacterials in the future.100

  • Importance of informing clinician if there is evidence of neurotoxicity (e.g., paresthesia, lethargy, confusion, dizziness, ataxia, nystagmus, speech disorders, apnea) or nephrotoxicity (e.g., decreased urine output).a

  • Patients should be warned that the drug may impair their ability to perform hazardous activities requiring mental alertness or physical coordination (e.g., operating machinery, driving a motor vehicle).a

  • Advise patients that diarrhea is a common problem caused by anti-infectives and usually ends when the drug is discontinued.100 Importance of contacting a clinician if watery and bloody stools (with or without stomach cramps and fever) occur during or as late as 2 months or longer after the last dose.100

  • Patients should be advised not to use any premixed, ready-to-use liquid preparations of colistimethate for nebulization and to discard any unused vials of premixed, ready-to-use liquid preparations of the drug that they may have in their possession.109 110

  • Importance of informing clinician of existing or contemplated therapy, including prescription and OTC drugs, and any concomitant illnesses.a

  • Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.a

  • Importance of advising patients of other important precautionary information.a (See Cautions.)

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Colistimethate Sodium

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Parenteral

For injection

150 mg (of colistin)*

Colistimethate Sodium for Injection

Coly-Mycin M Parenteral

Monarch

AHFS DI Essentials. © Copyright, 2004-2014, Selected Revisions June 19, 2013. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

100. Monarch Pharmaceuticals. Coly-mycin M parenteral (colistimethate) for injection, USP prescribing information. Bristol, TN; 2006 Oct.

101. Johnson S, Gerding DN. Clostridium difficile-associated diarrhea. Clin Infect Dis. 1998; 26:1027-36. [IDIS 407733] [PubMed 9597221]

102. Gerding DN, Johnson S, Peterson LR et al for the Society for Healthcare Epidemiology of America. Position paper on Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol. 1995; 16:459-77. [PubMed 7594392]

103. Fekety R for the American College of Gastroenterology Practice Parameters Committee. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. Am J Gastroenterol. 1997; 92:739-50. (IDIS 386628) [IDIS 386628] [PubMed 9149180]

104. American Society of Health-System Pharmacists Commission on Therapeutics. ASHP therapeutic position statement on the preferential use of metronidazole for the treatment of Clostridium difficile-associated disease. Am J Health-Syst Pharm. 1998; 55:1407-11. [IDIS 407213] [PubMed 9659970]

105. Wilcox MH.Treatment of Clostridium difficile infection. J Antimicrob Chemother. 1998; 41(Suppl C):41-6. [IDIS 407246] [PubMed 9630373]

106. Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacol. 1999; 33:960-7.

108. Anon. Choice of antibacterial drugs. Treat Guidel Med Lett. 2004; 2:20-22.

109. Food and Drug Administration. Public health advisory on colistimethate (marketed as Coly-Mycin M and generic products). Rockville, MD; 2007 June 28. From FDA website.

110. Food and Drug Administration. Information for healthcare professionals on colistimethate (marketed as Coly-Mycin M and generic products). Rockville, MD; June 28 2007. From FDA website.

111. Hodson ME, Gallagher CG, Govan JRW. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J. 2002; 20:658–64.

112. Jensen T, Pedersn SS, Garne S et al. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother. 1987; 19:831–8.

113. Valerius NH, Koch C, Hoiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet . 1991; 338:725–6.

114. Hoiby N, Frederiksen B, Pressler T. Eradication of early Pseudomonas aeruginosa infection. J Cystic Fibro. 2005; 4:49-54.

115. Frederiksen B, Koch C, Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol. 1997; 23:330–5.

116. Littlewood JM, Miller MG, Ghoneim AT et al. Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis. Lancet. 1985; 1:865. Letter. [PubMed 2858720]

117. Taccetti G, Campana S, Festini F et al. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Resp J. 2005; 26:458-61.

118. Marchetti F, Giglio L, Candusso M et al. Early antibiotic treatment of pseudomonas aeruginosa colonisation in cystic fibrosis: a critical review of the literature. Eur J Clin Pharmacol. 2004; 60:67-74. [PubMed 15004732]

119. Beringer P. The clinical use of colistin in patients with cystic fibrosis. Curr Opin Pulm Med. 2001; 7: 434-40. [PubMed 11706322]

120. Shirk MB, Donahue KR, Shirvani J. Unlabeled uses of nebulized medications. Am J Health-Syst Pharm. 2006; 63:1704-16 [PubMed 16960254]

121. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis. 2005; 40:1333-41. [PubMed 15825037]

122. Littlewood JM, Koch C, Lambert PA et al. A ten year review of colomycin. Respir Med. 2000; 94:632-40. [PubMed 10926333]

123. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med. 2003; 168:918-51. [PubMed 14555458]

124. Boyle MP. Adult cystic fibrosis. JAMA. 2007; 298:1787-93. [PubMed 17940235]

125. Mukhopadhyay S, Singh M, Cater JI et al. Nebulised antipseudomonal antibiotic therapy in cystic fibrosis: a meta-analysis of benefits and risks. Thorax. 1996; 51:364-8. [PubMed 8733486]

126. Webb AK, Dodd ME. Nebulised antibiotics for adults with cystic fibrosis. Thorax. 1997; 52(Suppl 2):S69-71. [PubMed 9155856]

127. Wood DM, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev. 2006.; 25;1:CD004197.

128. Ryan G, Mukhopadhyay S, Singh M. Nebulised anti-pseudomonal antibiotics for cystic fibrosis. Cochrane Database Syst Rev. 2003;3:CD001021.

129. Falagas ME, Kasiakou SK. Use of international units when dosing colistin will help decrease confusion related to various formulations of the drug around the world. Antimicrob Agents Chemother. 2006; 50:2274-5. [PubMed 16723606]

130. Alothman GA, Ho B, Alsaadi MM et al. Bronchial constriction and inhaled colistin in cystic fibrosis. Chest. 2005; 127:522-9. [PubMed 15705991]

131. Cunningham S, Prasad A, Collyer L et al. Bronchoconstriction following nebulised colistin in cystic fibrosis. Arch Dis Child. 2001; 84:432-3 . [PubMed 11316693]

132. Ratjen F, Rietschel E, Kasel D et al. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J Antimicrob Chemother. 2006; 57:306-11. [PubMed 16396919]

133. Reed MD, Stern RC, O’Riordan MA et al. The pharmacokinetics of colistin in patients with cystic fibrosis. J Clin Pharmacol. 2001; 41:645-54. [PubMed 11402633]

134. Kucers A, Crowe S, Grayson ML et al, eds. The use of antibiotics. A clinical review of antibacterial, antifungal, and antiviral drugs. 5th ed. Jordan Hill, Oxford: Butterworth-Heinemann; 1997: 667-75.

135. Falagas ME, Kasiakou SK, Tsiodras S et al. The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature. Clin Med Res. 2006; 4:138-46. [PubMed 16809407]

136. Li J, Rayner CR, Nation RL. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumanii. Antimicrob Agents Chemother. 2006; 50:2946-50. [PubMed 16940086]

137. Antoniadou A, Kontopidou F, Poulakou G et al. Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster. J Antimicrob Chemother. 2007; 59:786-90. [PubMed 17307769]

138. Paolino K, Erwin D, Padharia V et al. In vitro activity of colistin against multidrug-resistant gram-negative bacteria isolated at a major army hospital during the military campaigns in Iraq and Afghanistan. Clin Infect Dis. 2007; 45:140-1. Letter. [PubMed 17554723]

a. AHFS Drug Information 2007. McEvoy GK, ed. Colistimethate. Bethesda, MD: American Society of Health-System Pharmacists; 2007:476-78.

HID. Trissel LA. Handbook on injectable drugs. 17th ed. Bethesda, MD. American Society of Health-System Pharmacists; 2013:307-8.

Hide
(web3)